Related references
Note: Only part of the references are listed.Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer
Giuseppe Di Lorenzo et al.
BJU INTERNATIONAL (2011)
Patupilone in cancer treatment
Branislav Bystricky et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer
Mari Nakabayashi et al.
BJU INTERNATIONAL (2010)
Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study
Jean-Christophe Eymard et al.
BJU INTERNATIONAL (2010)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Should Extrapulmonary Small Cell Cancer Be Managed Like Small Cell Lung Cancer?
Sinead M. Brennan et al.
CANCER (2010)
Integrative Genomic Profiling of Human Prostate Cancer
Barry S. Taylor et al.
CANCER CELL (2010)
Epithelial-to-Mesenchymal Transition Promotes Tubulin Detyrosination and Microtentacles that Enhance Endothelial Engagement
Rebecca A. Whipple et al.
CANCER RESEARCH (2010)
Reciprocal Activation of Prostate Cancer Cells and Cancer-Associated Fibroblasts Stimulates Epithelial-Mesenchymal Transition and Cancer Stemness
Elisa Giannoni et al.
CANCER RESEARCH (2010)
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
Andrew J. Armstrong et al.
CLINICAL CANCER RESEARCH (2010)
Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer
Amina Zoubeidi et al.
CLINICAL CANCER RESEARCH (2010)
The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer
Yohann Loriot et al.
EUROPEAN JOURNAL OF CANCER (2010)
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
Shihua Sun et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Abiraterone Acetate Is Well Tolerated Without Concomitant Use of Corticosteroids
Gerhardt Attard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Philip W. Kantoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy
Charles J. Ryan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
Daniel C. Danila et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
Alison H. M. Reid et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Improved Endpoints for Cancer Immunotherapy Trials
Axel Hoos et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Multiple Roles of Chemokine (C-C Motif) Ligand 2 in Promoting Prostate Cancer Growth
Jian Zhang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance
Hiroshi Tanaka et al.
NATURE MEDICINE (2010)
Cabazitaxel
Matthew D. Galsky et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
G. L. Semenza
ONCOGENE (2010)
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
Philip A. Watson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Prostate cancer as a model for tumour immunotherapy
Charles G. Drake
NATURE REVIEWS IMMUNOLOGY (2010)
Microtubules and resistance to tubulin-binding agents
Maria Kavallaris
NATURE REVIEWS CANCER (2010)
Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer
C. Serrate et al.
ANNALS OF ONCOLOGY (2009)
Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features
Y. Loriot et al.
ANNALS OF ONCOLOGY (2009)
Integrated Data From 2 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials of Active Cellular Immunotherapy With Sipuleucel-T in Advanced Prostate Cancer
Celestia S. Higano et al.
CANCER (2009)
Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
Rong Hu et al.
CANCER RESEARCH (2009)
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
Piyush B. Gupta et al.
CELL (2009)
Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer
Mary-Ellen Taplin et al.
CLINICAL CANCER RESEARCH (2009)
Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes
Ricardo M. Attar et al.
CLINICAL CANCER RESEARCH (2009)
Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
Alain C. Mita et al.
CLINICAL CANCER RESEARCH (2009)
The Role of Androgen Receptor Mutations in Prostate Cancer Progression
G. N. Brooke et al.
CURRENT GENOMICS (2009)
Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
Gerhardt Attard et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes
Shannon M. Mumenthaler et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
Howard I. Scher et al.
LANCET ONCOLOGY (2009)
Paclitaxel, Estramustine and Carboplatin Combination Chemotherapy after Initial Docetaxel-Based Chemotherapy in Castration-Resistant Prostate Cancer
A. Sella et al.
ONCOLOGY (2009)
Identification of βArrestin2 as a corepressor of androgen receptor signaling in prostate cancer
Vijayabaskar Lakshmikanthan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Epothilones: tubulin polymerization as a novel target for prostate cancer therapy
James J. Lee et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2009)
Environment-mediated drug resistance: a major contributor to minimal residual disease
Mark B. Meads et al.
NATURE REVIEWS CANCER (2009)
Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family
Jianming Xu et al.
NATURE REVIEWS CANCER (2009)
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa
D. R. Berthold et al.
ANNALS OF ONCOLOGY (2008)
A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients
X. Pivot et al.
ANNALS OF ONCOLOGY (2008)
The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data
Cristiana Lo Nigro et al.
BJU INTERNATIONAL (2008)
A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel
Robert W. Ross et al.
CANCER (2008)
Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer - Results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel
Tomasz M. Beer et al.
CANCER (2008)
Crosstalk between the Androgen Receptor and beta-Catenin in Castrate-Resistant Prostate Cancer
Gang Wang et al.
CANCER RESEARCH (2008)
Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth
R. Bruce Montgomery et al.
CANCER RESEARCH (2008)
The epithelial-mesenchymal transition generates cells with properties of stem cells
Sendurai A. Mani et al.
CELL (2008)
Understanding the biology of bone metastases: Key to the effective treatment of prostate cancer
Christopher J. Logothetis et al.
CLINICAL CANCER RESEARCH (2008)
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2008)
Androgen receptor and growth factor signaling cross-talk in prostate cancer cells
Meng-Lei Zhu et al.
ENDOCRINE-RELATED CANCER (2008)
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
Gerhardt Attard et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer
Paul Baas et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models
Dimitri Pchejetski et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?
Pascal Seve et al.
LANCET ONCOLOGY (2008)
Clinical Development of Ixabepilone and Other Epothilones in Patients with Advanced Solid Tumors
Edgardo Rivera et al.
ONCOLOGIST (2008)
Prolonged Androgen Receptor Loading Onto Chromatin and the Efficient Recruitment of p160 Coactivators Contribute to Androgen-Independent Growth of Prostate Cancer Cells
Xu-Bao Shi et al.
PROSTATE (2008)
CYP17 inhibition as a hormonal strategy for prostate cancer
Alison H. M. Reid et al.
NATURE CLINICAL PRACTICE UROLOGY (2008)
A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer
Karsten Gravdal et al.
CLINICAL CANCER RESEARCH (2007)
HIF-1 and NF-κB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells
P. J. Maxwell et al.
ONCOGENE (2007)
Treatment outcomes of small cell carcinoma of the prostate - A single-center study
Philippe E. Spiess et al.
CANCER (2007)
Drug resistance and the solid tumor microenvironment
Olivier Tredan et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients - Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone
Jonathan E. Rosenberg et al.
CANCER (2007)
Increased metastatic lymph node 64 and CYP17 expression are associated with high stage prostate cancer
A. Stigliano et al.
JOURNAL OF ENDOCRINOLOGY (2007)
Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles
Kenji Tamura et al.
CANCER RESEARCH (2007)
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer
Elahe A. Mostaghel et al.
CANCER RESEARCH (2007)
Limited tissue penetration of taxanes: A mechanism for resistance in solid tumors
Alastair H. Kyle et al.
CLINICAL CANCER RESEARCH (2007)
In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer
Sanjeev Banerjee et al.
CANCER RESEARCH (2007)
Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells
Murielle Mimeault et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?
William K. Oh et al.
CANCER (2007)
Integrative molecular concept modeling of prostate cancer progression
Scott A. Tomlins et al.
NATURE GENETICS (2007)
Inappropriate activation of the androgen receptor by nonsteroids: Involvement of the Src kinase pathway and its therapeutic implications
Sonal J. Desai et al.
CANCER RESEARCH (2006)
Alterations in γ-actin and tubulin-targeted drug resistance in childhood leukemia
Nicole M. Verrills et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Interleukin 6, a nuclear factor-κB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-κB inhibition by PS-1145 enhances docetaxel antitumor activity
Josep Domingo-Domenech et al.
CLINICAL CANCER RESEARCH (2006)
A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer
William Berry et al.
CLINICAL GENITOURINARY CANCER (2006)
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
Eric J. Small et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes
Kazuki Yamanaka et al.
BJU INTERNATIONAL (2006)
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer
M Stanbrough et al.
CANCER RESEARCH (2006)
Randomized phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer
A Cabrespine et al.
UROLOGY (2006)
Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: A southwest oncology group trial S0111
M Hussain et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Chemotherapy for hormone-refractory prostate cancer: Now it's a question of When?
CJ Ryan et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Satraplatin in the treatment of hormone-refractory prostate cancer
CN Sternberg
BJU INTERNATIONAL (2005)
Survivin mediates resistance to antiandrogen therapy in prostate cancer
M Zhang et al.
ONCOGENE (2005)
Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts
LC Wu et al.
CANCER RESEARCH (2005)
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583)
EJ Small et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Do β-tubulin mutations have a role in resistance to chemotherapy?
HK Berrieman et al.
LANCET ONCOLOGY (2004)
High interstitial fluid pressure -: An obstacle in cancer therapy
CH Heldin et al.
NATURE REVIEWS CANCER (2004)
Molecular determinants of resistance to antiandrogen therapy
CD Chen et al.
NATURE MEDICINE (2004)
Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer
A O'Donnell et al.
BRITISH JOURNAL OF CANCER (2004)
HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability
IK Mellinghoff et al.
CANCER CELL (2004)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Exploiting tumour hypoxia in cancer treatment
JM Brown et al.
NATURE REVIEWS CANCER (2004)
Erk inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells
S Zelivianski et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Bcl-xL mediates a survival mechanism independent of the phosphoinositide 3-kinase/Akt pathway in prostate cancer cells
CC Yang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo
M Shionoya et al.
CANCER SCIENCE (2003)
The role of MAPK pathways in the action of chemotherapeutic drugs
S Boldt et al.
CARCINOGENESIS (2002)
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate
CN Papandreou et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Molecular biology of the androgen receptor
EP Gelmann
JOURNAL OF CLINICAL ONCOLOGY (2002)
Multidrug resistance in cancer: Role of ATP-dependent transporters
MM Gottesman et al.
NATURE REVIEWS CANCER (2002)
The development of androgen-independent prostate cancer
BJ Feldman et al.
NATURE REVIEWS CANCER (2001)
A family of drug transporters: The multidrug resistance-associated proteins
P Borst et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
